JP2013522239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522239A5 JP2013522239A5 JP2012557295A JP2012557295A JP2013522239A5 JP 2013522239 A5 JP2013522239 A5 JP 2013522239A5 JP 2012557295 A JP2012557295 A JP 2012557295A JP 2012557295 A JP2012557295 A JP 2012557295A JP 2013522239 A5 JP2013522239 A5 JP 2013522239A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- formulation
- solvent system
- api
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 35
- 238000009472 formulation Methods 0.000 claims description 27
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- 150000002772 monosaccharides Chemical group 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 14
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims description 8
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 8
- TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000012298 atmosphere Substances 0.000 claims description 6
- 229920002988 biodegradable polymer Polymers 0.000 claims description 6
- 239000004621 biodegradable polymer Substances 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 108091006006 PEGylated Proteins Proteins 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 229960002903 benzyl benzoate Drugs 0.000 claims description 4
- 239000003114 blood coagulation factor Substances 0.000 claims description 4
- 229940019700 blood coagulation factors Drugs 0.000 claims description 4
- -1 glycofural Chemical compound 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 239000003124 biologic agent Substances 0.000 claims description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 150000005690 diesters Chemical class 0.000 claims description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001600 hydrophobic polymer Polymers 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31366610P | 2010-03-12 | 2010-03-12 | |
| US61/313,666 | 2010-03-12 | ||
| PCT/US2011/028195 WO2011112996A2 (en) | 2010-03-12 | 2011-03-11 | Injectable drug delivery system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522239A JP2013522239A (ja) | 2013-06-13 |
| JP2013522239A5 true JP2013522239A5 (enExample) | 2014-04-24 |
Family
ID=44148866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557295A Pending JP2013522239A (ja) | 2010-03-12 | 2011-03-11 | 注射用薬物送達システム |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110229457A1 (enExample) |
| EP (1) | EP2544658A2 (enExample) |
| JP (1) | JP2013522239A (enExample) |
| CA (1) | CA2792771A1 (enExample) |
| WO (1) | WO2011112996A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9205150B2 (en) * | 2011-12-05 | 2015-12-08 | Incept, Llc | Medical organogel processes and compositions |
| JP2016506389A (ja) * | 2012-12-06 | 2016-03-03 | トビラ・セラピューティクス・インコーポレイテッド | オリゴヌクレオチド製剤 |
| EP3183026B1 (en) * | 2014-08-19 | 2019-10-30 | The Regents of The University of California | Implants for localized drug delivery and methods of use thereof |
| WO2017106833A1 (en) * | 2015-12-18 | 2017-06-22 | The University Of Akron | Peptidomimetic polymers as controlled release matrices for small molecules |
| JP7054793B2 (ja) * | 2017-07-07 | 2022-04-15 | パナソニックＩｐマネジメント株式会社 | 情報提供方法、情報処理システム、情報端末、及び情報処理方法 |
| CN110537097B (zh) * | 2017-07-07 | 2022-03-08 | 松下知识产权经营株式会社 | 信息提供方法、信息处理系统、信息终端及信息处理方法 |
| KR20200024758A (ko) * | 2017-07-07 | 2020-03-09 | 파나소닉 아이피 매니지먼트 가부시키가이샤 | 정보 제공 방법, 정보 처리 시스템, 정보 단말, 및 정보 처리 방법 |
| JP6924969B2 (ja) * | 2017-07-07 | 2021-08-25 | パナソニックＩｐマネジメント株式会社 | 情報提供方法、情報処理システム、情報端末、及び情報処理方法 |
| WO2019008971A1 (ja) * | 2017-07-07 | 2019-01-10 | パナソニックＩｐマネジメント株式会社 | 情報提供方法、情報処理システム、情報端末、及び情報処理方法 |
| EP3934663B1 (en) * | 2019-03-05 | 2024-06-26 | Dow Global Technologies LLC | Polyethyleneglycol derivatives for use in treating cancer and/or inducing caspase activity |
| EP4100075A4 (en) | 2020-03-20 | 2024-01-31 | The Regents of University of California | IMPLANTABLE DRUG RELEASE DEVICES FOR LOCALIZED DRUG RELEASE |
| US11344526B2 (en) | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11338119B2 (en) | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11173291B2 (en) | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| CN111956638B (zh) * | 2020-08-06 | 2023-01-24 | 上海宛文创业孵化器管理合伙企业(有限合伙) | 蓓萨罗丁或/和其药学上可接受的盐在制备抗肺动脉高压药物中的应用 |
| US11912696B2 (en) | 2021-10-01 | 2024-02-27 | Promega Corporation | Compounds and methods for detection of nitric oxide |
| CN116870238B (zh) * | 2023-08-25 | 2025-12-26 | 中国海洋大学 | 一种抑菌介孔淀粉止血粉及其制备方法 |
| WO2026018920A1 (ja) * | 2024-07-18 | 2026-01-22 | 国立大学法人九州大学 | 凍結乾燥装置、および、凍結乾燥試料とその製造方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4433101A1 (de) * | 1994-09-16 | 1996-03-21 | Bauer Kurt Heinz Prof Dr | Wasserlösliche Dextranfettsäureester und ihre Verwendung als Solubilisatoren |
| JP2002512597A (ja) * | 1996-12-20 | 2002-04-23 | アルザ コーポレイション | 注射可能な貯留槽ゲル組成物およびこの組成物の製造方法 |
| US6224893B1 (en) * | 1997-04-11 | 2001-05-01 | Massachusetts Institute Of Technology | Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering |
| US6472512B1 (en) * | 1998-07-21 | 2002-10-29 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
| EP1481695A1 (en) * | 1999-10-15 | 2004-12-01 | Genetics Institute, LLC | Formulations of hyaluronic acid for delivery of osteogenic proteins |
| US6703040B2 (en) | 2000-01-11 | 2004-03-09 | Intralytix, Inc. | Polymer blends as biodegradable matrices for preparing biocomposites |
| JP2003522154A (ja) * | 2000-02-08 | 2003-07-22 | アラーガン、インコーポレイテッド | ボツリヌス毒素医薬組成物 |
| CN1283215C (zh) * | 2000-06-28 | 2006-11-08 | A·J·舒克拉 | 生物活性物质的可生物降解载体和释放系统 |
| JP4817088B2 (ja) * | 2000-10-10 | 2011-11-16 | 株式会社林原生物化学研究所 | 塞栓材料 |
| AU2002320122B2 (en) * | 2001-06-21 | 2007-07-26 | Genentech, Inc. | Sustained release formulation |
| WO2003072155A1 (en) * | 2002-02-21 | 2003-09-04 | Encelle, Inc. | Cross-linked bioactive hydrogel matrices |
| EP1555278A1 (en) | 2004-01-15 | 2005-07-20 | Innocore Technologies B.V. | Biodegradable multi-block co-polymers |
| DE102004021240B4 (de) * | 2004-04-30 | 2008-07-31 | Infineon Technologies Ag | Verfahren zur Herstellung einer Halbleiter-Schaltungsanordnung in BiCMOS-Technologie |
| GB0412866D0 (en) * | 2004-06-09 | 2004-07-14 | Novartis Ag | Organic compounds |
| AU2005316545A1 (en) * | 2004-12-15 | 2006-06-22 | Qlt Usa, Inc. | Sustained delivery formulations of octreotide compounds |
| EP2004252A2 (en) | 2006-03-15 | 2008-12-24 | SurModics, Inc. | Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof |
| WO2009005718A1 (en) * | 2007-06-28 | 2009-01-08 | Surmodics, Inc. | Polypeptide microparticles having sustained release characteristics, methods and uses |
| WO2010141553A1 (en) * | 2009-06-02 | 2010-12-09 | Surmodics, Inc. | SILANE-FUNCTIONALIZED HYDROPHOBIC a(1→4)GLUCOPYRANOSE POLYMERS AND POLYMERIC MATRICES FOR IMPLANTATION OR INJECTION |
-
2011
- 2011-03-11 JP JP2012557295A patent/JP2013522239A/ja active Pending
- 2011-03-11 CA CA2792771A patent/CA2792771A1/en not_active Abandoned
- 2011-03-11 EP EP11710949A patent/EP2544658A2/en not_active Withdrawn
- 2011-03-11 WO PCT/US2011/028195 patent/WO2011112996A2/en not_active Ceased
- 2011-03-11 US US13/046,547 patent/US20110229457A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Integration of human umbilical cord mesenchymal stem cells-derived exosomes with hydroxyapatite-embedded hyaluronic acid-alginate hydrogel for bone regeneration | |
| US20230414769A1 (en) | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | |
| US8987230B2 (en) | Hybrid gel comprising chemically crosslinked hyaluronic acid derivative and pharmaceutical composition comprising the same | |
| JP2013522239A (ja) | 注射用薬物送達システム | |
| Matricardi et al. | Polysaccharide hydrogels: Characterization and biomedical applications | |
| Kanazawa et al. | Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG–PCL nanomicelles | |
| JP2014514275A5 (enExample) | ||
| US20080220030A1 (en) | Nanoparticles Comprising Chitosan and Cyclodextrin | |
| JP2010534708A (ja) | 両親媒性ポリマーとｂｍｐファミリーに属する骨形成タンパク質との複合体 | |
| JP2013525414A5 (enExample) | ||
| KR20110118779A (ko) | 국소 투여용으로 적당한 이미다조퀴놀린（아민）및 이의 유도체를 포함하는 약학 조성물 | |
| JP2008533108A (ja) | 生物学的に活性な分子の投与系としての、キトサンとポリエチレングリコールとのナノ粒子 | |
| CA2797058A1 (en) | Conjugated blood coagulation factor viii | |
| CA3216091A1 (en) | Oral delivery of oligonucleotides | |
| Li et al. | Structural design and physicochemical foundations of hydrogels for biomedical applications | |
| CN117545509A (zh) | 寡核苷酸的口服递送 | |
| US9644039B2 (en) | Acid-degradable and bioerodible modified polyhydroxylated materials | |
| US20170119668A1 (en) | Polymeric particles, method for cytosolic delivery of cargo, methods of making the particles | |
| Lin et al. | Biodegradable micelles from a hyaluronan-poly (ε-caprolactone) graft copolymer as nanocarriers for fibroblast growth factor 1 | |
| Hernandez-Patlan et al. | Green Biopolymers as Carriers for Innovative Drug Delivery | |
| US20250032478A1 (en) | Solid forms of resiquimod and formulations thereof | |
| Clapacs | Nanoengineered Constructs for Immunomodulatory Therapeutic Delivery | |
| HK1246333B (zh) | 制备具有优异的肽和蛋白结合性质的接枝共聚物赋形剂的方法 | |
| HK1206378B (en) | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | |
| WO2017084696A1 (fr) | Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique |